Form 4: United Therapeutics CEO Executes Planned Stock Sale

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the CEO sold the 9,500 shares in a series of transactions on June 10, 2026.
• The sales were executed at weighted average prices ranging from $539.12 to $557.04 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and represent routine financial management by the executive.

Positives

• The transactions were executed under a pre-planned 10b5-1 program, indicating the sales were not based on non-public information.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including 50,013 shares held directly and substantial holdings in family trusts.

Negatives

• The sale represents a reduction in the CEO's direct equity holdings.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, which may lead to further periodic selling pressure.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the end of 2026 or until 1,734,410 options have been exercised.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in management's outlook on company performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice among S&P 500 and biotech executives to avoid potential insider trading allegations.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive diversification strategies.

Stakeholder Impact

• Shareholders should note the ongoing, scheduled nature of these sales, which are designed to minimize market impact.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Stock Options, Biotech